Biocon Q2 FY27: Consolidated PAT Falls 57% YoY on Biosimilars Margin Collapse
PAT -57.3% YoY · revenue +2.2% · margins compressing
₹4,388.9 Cr
+2.2% YoY
₹56.7 Cr
-57.3% YoY
1.28%
-1.7pp YoY
₹0.25
Biocon's consolidated profit for the quarter (including minority interest) fell 57.3% year-on-year to ₹56.7 Cr in Q2 FY27, from ₹132.8 Cr in Q2 FY26, even as consolidated revenue rose a modest 2.2% YoY to ₹4,388.9 Cr (₹4,295.5 Cr). The decline is sequential too — PAT is down 58.6% from ₹136.8 Cr in Q1 FY27 on revenue up just 1.2% QoQ. This is squarely a margin story: net profit margin compressed to 1.3% from 3.0% a year ago and 3.1% last quarter, and consolidated profit before tax (after the exceptional charge) fell 68.0% YoY to ₹54.8 Cr. Standalone (parent-only) PAT, by contrast, was ₹91.7 Cr — higher than the consolidated figure, underscoring that subsidiaries were a net drag this quarter.
Q2 FY-2027 vs prior quarters
The bridge sits almost entirely in the Biosimilars segment: its revenue grew 3.2% YoY to ₹2,808.6 Cr, but segment profit before tax collapsed 80.6% YoY to ₹32.5 Cr from ₹167.2 Cr, pulling segment PBT margin down to 1.2% from 6.1%. Group-level cost of materials consumed rose 22.1% YoY to ₹1,669.0 Cr and other expenses rose 15.7% YoY to ₹1,189.2 Cr — both well ahead of the 2.2% revenue growth — while employee costs were roughly flat (-0.7% YoY) and finance costs fell 11.8% YoY to ₹240.1 Cr on continued debt paydown. Syngene (Services segment) profit fell 37.0% YoY to ₹53.7 Cr as its revenue declined 8.6% YoY to ₹832.7 Cr, though it swung from a ₹5.7 Cr segment loss in Q1 FY27 back to profit. Generics was the one bright spot, narrowing its segment loss to ₹30.4 Cr from ₹69.2 Cr a year ago. The ₹6.7 Cr exceptional charge (employee termination costs) was broadly similar in scale to the ₹11.9 Cr and ₹13.5 Cr charges in the year-ago and prior quarters respectively — stripping it out, adjusted PAT YoY decline is ~56.2%, barely different from the 57.3% reported, so this is a genuine operating deterioration rather than a one-off distortion.
The stock went into the print at ₹345.65, down 6.5% over the past month of trading.
FY27 biosimilar margins to remain mid-20s, with meaningful acceleration in H2 from five new product ramps (Aflibercept, Denosumab, Aspart, Ustekinumab, Bevacizumab). Syngene expected single-digit revenue degrowth full year, EBITDA margins back to mid-20s by FY28. Annual launches targeted in US/Europe through decade-end
— This quarter: missed
Management's prior concall guidance (August 2026) had called for FY27 biosimilar margins to stay in the mid-20s with 'meaningful acceleration in H2' from five new product ramps — Aflibercept, Denosumab, Aspart, Ustekinumab and Bevacizumab — and for Syngene to post single-digit full-year revenue degrowth en route to mid-20s EBITDA margins by FY28. This quarter runs counter to the biosimilar part of that guidance: segment profitability moved sharply in the wrong direction just as H2 began. Syngene's print is at least directionally consistent with its guided degrowth. No formal analyst consensus for this specific quarter could be confirmed via search, as results were only announced today (November 4, 2026); vsStreet is therefore unknown rather than assumed, and no management press release accompanying these results was available to cross-check against the numbers. Concurrently, the company disclosed two biosimilars pipeline developments — an expanded market entry for Yesintek and an early launch for Pebrilzo following a patent settlement — alongside a CTO transition (Mandar Ghatnekar's exit effective December 31, 2026, succeeded by Mukesh Rathi from January 1, 2027) and a minor ₹3.04 Cr GST order; none of these directly explain the quarter's margin compression.
W1
Whether Biosimilars segment PBT recovers toward FY27 guidance of mid-20s margins as the five new product ramps (Aflibercept, Denosumab, Aspart, Ustekinumab, Bevacizumab) contribute in H2 — this quarter's segment PBT margin was 1.2%.
W2
Syngene's revenue trajectory against management's full-year single-digit degrowth guidance (down 8.6% YoY this quarter) and its stated path to mid-20s EBITDA margins by FY28.
W3
Whether the ₹1.9 Cr net tax credit that cushioned this quarter's PAT normalizes next quarter, which would pressure PAT further absent operating recovery.
The ₹56.7 Crore Profit Biocon Can't Explain
Reported PAT collapsed 57% YoY to ₹56.7 Cr (1.3% NPM), yet management claimed biosimilar EBITDA margins of 22%. The gap—more than 20 percentage points—remains unreconciled. Logistics deferral and freight costs explain part of it, but not the magnitude.
₹56.7 Cr
-57.3% YoY
₹623 Cr
22% margin
~20pp
NPM 1.3% vs EBITDA 22%
On paper, Q2 revenue of ₹4,389 Cr grew 2.2% YoY, a soft miss against mid-teens guidance from the prior quarter. But the real story is profit: PAT crashed 57.3% to ₹56.7 Cr, compressing net margins to 1.3%. Management blamed a ~₹135 Cr (~5%) logistics deferral and freight/solvent cost headwinds, but the magnitude of margin collapse—from claimed 22% EBITDA on biosimilars to 1.3% NPM company-wide—leaves a 20-percentage-point gap that no one adequately explained on the call.
Where the profit went
Claims vs. what holds up
"Biosimilar margins at mid-20s EBITDA"
"Underlying business remains strong"
"Yesafili off to encouraging start with 34% US market share"
"5% deferral is one-off Q2 situation, booked in October"
"H2 biosimilars to show double-digit growth"
The first two claims collapse under scrutiny. Q2 delivered 2.2% revenue growth YoY and -57.3% PAT decline—neither 'strong'—and the PAT number directly contradicts the mid-20s margin assertion. Yesafili's 34% US market share and >50% market access are credible and represent genuine momentum, as do the five new European biosimilar launches (Ustekinumab, Denosumab, Aflibercept, Aspart, Bevacizumab) gaining 20 tender awards. The deferral story—₹135 Cr logistics delay, shipments made but revenue unrecognized until October—is plausible and management stood by it. But the H2 'double-digit growth' guidance, offered without numeric PAT or margin targets, leaves execution risk elevated.
What changed on this call
Positive: Brazil Pertuzumab partnership closed (₹400 Cr over 10 years, supplies begin Q4 FY27)—a material, multi-year revenue floor not present prior. Five new biosimilar European launches imminent with 20 tender awards; Pebrizo (Pertuzumab) EU/UK launch Q1 2027, US Q3 2028; regulatory risk de-risked via Genentech settlement. Syngene sequential improvement from Q1, margin recovery trajectory intact.
Negative: H1 biosimilar growth 9% YoY (vs. mid-teens prior guidance)—a meaningful undershoot. Q2 deferral and margin collapse signal supply chain stress during a period of claimed launch readiness. No new numeric targets for FY27 biosimilar margins or FY28 PAT; prior 'mid-20s margin' guidance not reaffirmed verbally, though not withdrawn. Analysts pressed hard on margin bridge; management's answer (deferral + freight) insufficiently explained the 20pp gap.
How the street is positioned
The stock has lost 24.5% from its all-time high of ₹487.75, trading now at ₹368.05, roughly at its 50-day SMA (₹368.06) but below the 200-day (₹390.06). Technically, this is a pullback into support, not a crash—RSI at 58.2 is neutral, volume normal. But institutional positioning tells a nuanced story: FII ownership inched up to 8.14% from 7.52% last quarter (+0.62pp), suggesting conviction holders not fleeing. DII edged down (-0.69pp) to 23.38%, while promoter ownership remained stable at 44.68%. Most telling: in recent block deals, institutional buyers (SBI MF, HDFC MF, ICICI Prudential, Société Générale) accumulated at ₹400, while Mylan divested the same size at the same price. That's institutional confidence—buying weakness, not panic selling.
The bull-bear ledger
Brazil ₹400 Cr partnership concrete, multi-year revenue floor
Five new biosimilar launches with regulatory clarity (Pebrizo timeline confirmed)
Yesafili 34% US market share, >50% market access, surpassing originators
Syngene profitability inflection underway (18.5% EBITDA margin H1, track to mid-20s FY28)
Interest cost declining 12% YoY, balance sheet strengthening
PAT collapsed 57.3% YoY, margin guidance not reaffirmed, credibility tested
Q2 logistics deferral signals supply chain fragility during new launch ramps
H1 biosimilar growth 9% YoY vs. mid-teens guidance—execution lag
Biosimilar EBITDA-to-PAT bridge remains unreconciled; unaccounted items suspected
H2 'double-digit growth' claimed but no numeric margin or PAT targets given
Risks, ranked by severity to holders
Margin compression vs. EBITDA claims
HighQ2 PAT 1.3% vs. claimed biosimilar EBITDA 22%. Gap unreconciled and larger than deferral + freight explains. If this persists, mid-20s FY27 margin target is unrealistic; earnings power significantly lower.
New product execution on five launches
HighYesafili, Aspart, Denosumab, Bevacizumab, Ustekinumab ramps must achieve claimed pricing and market share. Any delayed adoption or competitive entry erodes H2 acceleration narrative. Analysts pressed hard; management deferred customer detail offline.
Supply chain fragility
Medium₹135 Cr Q2 deferral due to logistics/geopolitical delays. Booked in Oct, but pattern suggests just-in-time vulnerabilities during ramp phases. Further disruptions could cascade into H2 and Q3 revenue recognition.
Biosimilar ASP erosion from competitive entry
MediumYesafili, Aspart in crowded biosimilar market; Sandoz, Teva, other competitors entering via Part B/D routes. Management defended on 'value not price' but industry-wide pricing pressure visible. Durability of 34% Yesafili share unproven.
Currency headwinds
MediumManagement cited 6–8% FX benefit but rupee depreciation not guaranteed. Adverse movement compresses reported margins; generics particularly exposed to crude-linked input costs.
Generics margin recovery stalling
Low-MediumH1 EBITDA margin 8%, up from 1%, but this recovery not yet flowing to PAT. Freight/solvent easing will help, but API/formulations ASP pressure remains. Syngene client consolidation (post-Viatris) is a future headwind.
The debate
The honest read: Biocon is in a structural inflection—five new launches, a landmark Brazil deal, and Syngene recovery are genuine. But Q2's execution gap (promised growth, delivered stall; claimed margins, showed collapse) has tested credibility. The margin bridge remains unexplained, and management's refusal to reaffirm numeric targets is a tell. This is not a broken story, but it's not a clear buy at current weakness either. Holders should see H2 as a proof point: if biosimilar growth does hit double-digits and margins recover to high-teens, the stock rebounds and the bulls win. If H2 stumbles, -24.5% from ATH looks cheap in retrospect.
1 · H2 FY27 biosimilar growth rate (Q3 / Q4 updates)
Management guided 'double-digit growth' but gave no numeric target. Watch for incremental quarterly guidance, tender award announcements, and Yesafili/Aspart inventory build signals. If 9% YoY H1 accelerates to 15%+ in H2, the narrative holds. If it stalls near 10%, execution risk is real.
2 · Q3 margin bridge / PAT recovery
The ₹135 Cr deferral was booked in October (Q3). Watch whether Q3 PAT rebounds meaningfully once this revenue lands. If Q3 PAT stays compressed despite deferral recognition, the unaccounted 20pp margin gap becomes a structural issue, not a one-off.
3 · Brazil Pertuzumab ramp and Pebrizo EU/UK launch (Q4 / Q1 2027)
First supplies to Bahiafarma/Bionov in Q4 FY27, then Pebrizo commercial availability EU/UK in Q1 2027. Any regulatory slippage or supply-side hiccups signal execution risk. Conversely, on-time launch confirms management's de-risking narrative.
Biocon is a steady business having a lumpy quarter, not a broken franchise. Long-term structural tailwinds (biosimilar adoption, manufacturing moat, geographic diversification) are real. But near-term credibility is on the line: claimed mid-20s margins are not materializing, guidance has been missed, and the supply chain hiccup (₹135 Cr deferral) is a warning sign during a period of supposed launch momentum.
The number to track from here is H2 biosimilar growth. If it hits 15%+ YoY and margins recover visibly, the -24.5% drawdown from ATH becomes a gift. If it stalls at 10% or below, execution risk migrates from 'medium' to 'high,' and the stock likely re-tests lower support. Holders should hold for the H2 print and Q3/Q4 catalysts; new buyers might wait for that proof point.
Biosimilar Scale on the Horizon—Watch for Margin Proof in Q2
Biocon reports Q2 FY27 on November 4 with the Street expecting 14–15% revenue growth and sustained EBITDA margins near 20%, riding biosimilar launches and regulatory wins. Key: How much Yesintek and Pebrilzo contribute, and where profits settle.
Biocon reports Q2 FY27 results on November 4, with the board convening to approve unaudited standalone and consolidated financials for the quarter and half-year ended September 30, 2026. The quarter caps a period of significant regulatory momentum—EMA CHMP endorsement of the pertuzumab biosimilar (Pebrilzo), FDA supplemental approval for Yesintek autoinjector formats, MHRA clearance for the Malaysia fill-finish unit, and market expansion into nine countries for the ustekinumab biosimilar. The Street is watching whether this regulatory tick translates to revenue acceleration and, critically, whether gross and EBITDA margins hold near the Q1 baseline.
What to Expect
~₹4,600–4,700 Cr
Q1 FY27: ₹4,391 Cr (9% YoY); 14–16% growth expected reflects biosimilar ramp
~₹920–980 Cr at 20–21%
Q1 margin: 21%; sustained margin critical after R&D/capex for biosimilar launches
~₹140–160 Cr
Q1 delivered ₹141 Cr; profit growth pace will signal FY27 trajectory vs. 184% analyst estimate
GST contingency
₹3.04 Cr demand (₹1.86 Cr tax + ₹1.18 Cr interest, Oct 10 order) will cloud reported profit; may contest
Strong vs. weak quarter: A strong print = revenue >15% YoY, EBITDA margin ≥21%, and meaningful contribution from Yesintek/Pebrilzo ramp (early-stage revenues, though). Weak = revenue <12%, margin compression to <19%, or guidance withdrawn on GST / regulatory headwinds. The Street is hunting for proof that biosimilar launches move the needle; Q2 is the first real snapshot.
On Track?
Q1 FY27 revenues grew 9% YoY to ₹4,391 Cr, and EBITDA margin held at 21%. Analyst consensus forecasts 14.6% revenue growth for full FY27, implying Q2–Q4 should accelerate from Q1's 9% base. The recent regulatory wins (EMA, FDA, MHRA approvals in Sep–Oct) landed too late for material Q1 contribution but are firsting in Q2. If Q2 revenues grow 14–16% and margin holds at ~20%, Biocon remains on track; <12% growth or margin compression <19% would signal execution drag. The board will also likely give updated FY27 guidance, critical given the 184% net profit growth analyst estimate for the year—that's a stretch target requiring sustained operating leverage.
What the Street Says
Since Last Quarter
Oct 29
Science Magazine Award — Top 20 Global Biotech Employers (13th rank)
Talent; routine
Oct 26
Yesintek biosimilar: 9 new market entries (Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Africa, Thailand)
Revenue ramp; material
Oct 14
Pebrilzo (bPertuzumab) — Global settlement with Genentech; early licensed launch approved
Regulatory; material
Oct 10
GST Order-In-Original: ₹1.86 Cr tax + ₹1.18 Cr interest + penalty demand (Visakhapatnam)
Contingent liability; disclosure required
Oct 1
ESOP Grant: 94.6 lakh stock options under 'Growth Accelerator' Plan at ₹57.88 exercise price
Dilution neutral (future); retention tool
Sep 25
Malaysia MHRA Approval: Biocon Malaysia fill-finish unit for Semglee (insulin glargine)
Capex validation; regulatory
Sep 21
EMA CHMP Positive Opinion: Pebrilzo (pertuzumab biosimilar) — first under accelerated pathway
Landmark; de-risk European launch
Sep 8
Brazil Supply Contract: 10-year pertuzumab supply deal (HER2+ breast cancer therapy)
Revenue contract; visibility
Aug 26
Mylan Inc. Shareholding: Revised disclosure — sale of 9.2 Cr shares (5.64% stake); post-sale holdings clarified
Promoter churn; monitoring
Aug 25
Japan MHLW Approval: Pegfilgrastim biosimilar (Neulasta substitute) launch
New geography; minor
Aug 6
AGM: Auditor change (B S R → S.R. Batliboi & Associates); Director re-appointment
Corporate governance; routine
Highlights: The quarter is dominated by biosimilar regulatory momentum—EMA CHMP for Pebrilzo (first under EU's accelerated pathway), 9 new markets for Yesintek, Japan MHLW approval for pegfilgrastim, and Malaysia MHRA clearance for fill-finish capacity. These de-risk geographic expansion and ramp assumptions, but actual revenue realization will show in Q2–Q3 numbers. Watch: GST order (Oct 10, ₹3.04 Cr) is a contingent liability; company will likely contest and may not accrue in Q2 if management believes defensible. Mylan's exit from 5.64% stake (Aug 26) is neutral—no new promoter pledges noted, shareholding stable. ESOPs are retention-positive for a talent-intensive biotech. Overall tone is operationally constructive but balance-sheet contingencies and capex absorption (Malaysia facility, Indian expansions) will pressure near-term FCF.
1 · Biosimilar contribution breakdown
Management must separately disclose revenue from Yesintek (ustekinumab), Pebrilzo (pertuzumab), and pegfilgrastim in Q2. Early ramps in new geos rarely show full-scale volume by quarter-end; expect modest contribution but ask for trajectory guidance. The 184% FY27 profit growth estimate hinges on biosimilar margin sustainability as volumes grow.
2 · EBITDA margin & capex guidance
If Q2 margin holds 20–21% despite biosimilar investment and R&D spending, Street's FY27 guide (14.6% revenue, 184% profit growth) looks credible. Any compression to ₹300 Cr (for capacity / GMP) would signal margin headwind. Ask specifically about Malaysia facility ramp and inventory build for Yesintek/Pebrilzo launches.
3 · FY27 full-year guidance and GST contingency
Updated FY27 revenue, EBITDA, and PAT guidance will reset Street expectations. The 184% profit growth estimate seems dependent on operating leverage at higher scales; confirm it's reachable. Also: GST order (Oct 10)—will management accrue the full ₹3.04 Cr liability, contest it, or note it as a contingent? Clarity on liability treatment (P&L impact vs. balance-sheet reserve) is material for reported profit.
Biocon enters Q2 with a tailwind of regulatory approvals and biosimilar market entry, but execution risk is real. Q1 showed 9% revenue growth and 21% EBITDA margin; Q2 needs to prove the biosimilar launches drive 14–16% growth without margin compression, and that full-year profit can substantiate the Street's 184% growth estimate. The ₹351.8 stock price has run from ₹318 lows but remains 27% below the ₹447 consensus target—plenty of room if guidance is confident and margins hold. Watch the biosimilar revenue splits, capex outlook, and the GST liability treatment; those three will shape the post-result rally or retrenchment.
Soft growth, collapsed PAT mar H2 ramp confidence gap
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Claimed mid-20s FY27 biosimilar margins; Q2 delivered only 1.3% PAT. Guidance margin target not withdrawn but clearly not tracking.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Biocon is in a structural inflection with five new biosimilar launches driving H2 momentum and a landmark ₹400 Cr Brazil partnership beginning Q4, but Q2's 2.2% revenue growth and 57% PAT collapse contradict management's confidence. Execution risk on new launches is medium; currency headwinds and prior logistics deferral signal supply chain fragility.
₹4388.9 Cr
Revenue · +2.2% YoY₹56.7 Cr
Reported PAT · −57.3% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Biosimilars H1 EBITDA margin at 24%
MISSQ2 company NPM 1.3% (₹56.7 Cr PAT on ₹4389 Cr revenue), incompatible with 24% margin
Underlying business remains strong
OVERSTATEDRevenue growth 2.2% YoY, PAT down 57.3% YoY—both soft vs prior guidance expectations
$100 million new US contracts won
METClaimed in opening remarks; analysts queried but detail withheld. New product launches (Yesafili, Aspart) driving this, not fully validated
Strong momentum in Yesafili (Aflibercept)
OVERSTATEDManagement described Yesafili as off to 'encouraging start' but growth underpinned by only 2.2% revenue YoY; specific Yesafili revenue not disclosed
5% revenue deferral one-off, booked in October
METCFO confirmed ~₹135 Cr (~5% of biosimilar business), logistics/geopolitical causes, shipped but not revenue-recognized in Q2. Visibility exists but execution issue confirmed
Earnings quality
What changed since the last call
New product launch visibility
UpgradeUstekinumab, Denosumab, Aflibercept, Aspart all launched in Europe; 20 tender awards in major markets. Not in prior call; confirms ramp readiness.
Brazil Pertuzumab deal closed
Upgrade₹400 Cr 10-year contract with Bahiafarma/Bionov vs 'anticipated' before. Adds visible revenue stream Q4 FY27 onwards.
H1 biosimilar growth: 9% vs prior guidance mid-20s
DowngradeGuidance had implied stronger H1 pace. 9% YoY is soft; offset by claim that H2 will be 'strong.'
Generics profitability recovery
UpgradeH1 FY27 ₹120 Cr EBITDA (15% margin) vs negative in prior year. Reflects scale-up and cost discipline, but not captured in Q2 PAT.
The Q&A
Analysts pressed hard on deflationary Yesafili launch (Surya Patra, Phillip Capital), Aspart commercialization cadence (Damayanti Keral, HSBC), and biosimilar margin trajectory. Management defended by emphasizing pricing power via patient outcomes, not lowest price, and deferred significant customer details to off-call discussions. Held firm on H2 stronger, but withheld numeric targets—cautious posture.
New contracts / Yesafili — Surya Patra, Phillip Capital
AnsweredFresh launches, primarily Yesafili. Market share 34% in US alone; has surpassed originators. Durable opportunity with market access >50%, competing with ranibizumab.
5% deferral nature — Surya Patra, Phillip Capital
AnsweredOne-off Q2 situation: products shipped but not revenue-recognized due to logistics delays. Booked in October; Q3 will show those revenues. Not run-rate.
Pertuzumab opportunity timeline — Surya Patra, Phillip Capital
AnsweredBrazil starts Q4 FY27 (first piece). Europe Q4 FY27 (27 markets). US Q3 2028 (time to prepare). Tiered negotiation complete; global settlement with Genentech de-risks launch.
Yesafili competitive moat — Joshua Salsi, Biocon commercial lead
AnsweredAflibercept 2mg remains durable opportunity despite ranibizumab transition. >50% market access established, GPO partnerships secured. Yesafili profitable, not competing on price.
Aspart market share & ramp — Damayanti Keral, HSBC
PartialInsulin franchise sub-100M to 200-250M+; Glargine ongoing. Aspart cautious ramp: capacity builds, supply as we add customers. Legacy Glargine demand exceeds supply; not demand problem.
Biosimilar EBITDA margin bridge Q2→H2 — Charul Agrawal, Bank of America
PartialSales cutoff shifted to October. Margins either gross or EBITDA need adjustment for deferral extent. H2 expected strong growth vs H1. Strong order visibility on Aflibercept, Aspart, Ustekinumab, Pertuzumab. Inventory buildup expected.
Semaglutide competition & Biocon differentiation — Kenil Mehta, Boring AMC
PartialFermentation significantly cuts API cost and drug substance cost; requires rare manufacturing/scientific capability. Biocon fermentation-strong, differentiated vs chemical competitors. Detailed offline discussion offered.
Generics API & formulations growth segmentation — Sidharth Negandhi, CWC Advisors
PartialAPI rock-solid, strong portfolio, steady growth. Formulations strong in US; GLP-1 franchise growing (liraglutide market leader). Investments realized over time. Detailed discussion offline.
Interest cost & depreciation trend — Damayanti Keral, HSBC
AnsweredInterest declining 12% YoY to ₹240 Cr from ~₹273 Cr prior; will continue as debt retires. Depreciation in line with intangibles capitalized for new launches; 10-12 year useful life. Not large increase hereafter.
Biosimilar growth acceleration H2 target — Tushar Manudhane, Motilal Oswal
PartialExpecting strong performance, double-digit growth. Currency benefit 6-8% depending quarter/period. Performance tracked in dollars; reported rupee benefits if rupee depreciated.
Guidance
H2 FY27 stronger than H1; biosimilar double-digit growth
MediumBased on five new launches, but no numeric revenue target. Prior guidance implied mid-teen growth for FY27 biosimilars; 9% H1 undershoot requires significant H2 acceleration.
FY27 biosimilar margins remain mid-20s
LowNot reaffirmed verbally this call; Q2 delivered 1.3% PAT vs claimed 22%+ EBITDA. Management silent on whether prior target still in play.
Biosimilar EBITDA margins: mid-20s range, improved in H2
LowPrior stated target. Current deferral and PAT collapse suggest significant unreconciled gap. Management emphasized H2 visibility but did not quantify margin target.
Syngene EBITDA margins: back to mid-20s by FY28
MediumH1 ₹291 Cr EBITDA on ₹1,569 Cr revenue = 18.5%. H2 trajectory not specified, but sequential improvement confirmed from Q1.
Capex for new launches and capacity expansion ongoing
MediumMalaysia insulin line, expanded manufacturing for new biosimilar ramps. No total capex target given; expected to be material but not quantified.
Risks the call surfaced
New product execution
HighFive biosimilar launches promised for H2; Yesafili already 34% market share US but further growth dependent on payer penetration. Aspart supplied to closed-door networks; commercial expansion slow per Q&A.
Supply chain & execution
Medium~₹135 Cr (~5% biosimilar revenue) deferred in Q2 due to logistics/geopolitical issues. Booked in October, but pattern suggests fragility in just-in-time supply model, especially with new launch ramps.
Margin compression
HighQ2 PAT ₹56.7 Cr (1.3% NPM) vs claimed ₹623 Cr EBITDA (22%) biosimilar margin. Large gap unreconciled in call; suggests non-operating charges, tax headwinds, or valuation adjustments not disclosed.
Currency and commodity headwinds
MediumFreight costs ~$5 Cr, solvent costs ~$5 Cr impacting H1 margins. Currency benefit claimed 6-8% but not guaranteed; commodity prices volatile. Generics particularly exposed to crude-linked inputs.
Biosimilar pricing/competition
MediumYesafili faces potential ranibizumab competition and future novel therapies. Kenil Mehta (Boring AMC) noted semaglutide players (Sandoz, Teva) monetizing via Part B routes; Biocon Part B/D margins at risk if competition consolidates share.
Management
Score 6/10. Selective transparency. Detailed on strategy and regulatory milestones but guarded on product-level financials and customer lists. Deferred specifics on generics/biosimilar segment splits offline. NPM collapse (1.3% vs 24% EBITDA claim) not adequately reconciled in call. Track record mixed. H1 FY27 biosimilar 9% growth vs mid-teen prior guidance = miss. Interest cost declining 12% YoY (positive). Syngene sequential improvement (positive). But 5% Q2 deferral signals supply chain friction. PAT → EBITDA bridge unreconciled.
1 · Q4 FY27 (Oct-Dec 26)
Brazil Pertuzumab supplies begin; new insulin capacity comes online
2 · Q1 FY27 (Jan-Mar 27)
Pebrizo (Pertuzumab) launches in EU & UK; Aspart capacity ramp in Malaysia
3 · Q3 2028
Pebrizo US launch (post-regulatory approval); major US revenue upside
Execution risk on new launches is medium; currency headwinds and prior logistics deferral signal supply chain fragility.